Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does INFLIXIMAB Cause Small intestinal obstruction? 351 Reports in FDA Database

Grow Your Own Natural Pharmacy at Home

Medicinal Garden Kit — 10 healing herbs, 4,818 seeds + step-by-step guide.

Get the Kit

According to the FDA Adverse Event Reporting System (FAERS), 351 reports of Small intestinal obstruction have been filed in association with INFLIXIMAB (Renflexis). This represents 0.3% of all adverse event reports for INFLIXIMAB.

351
Reports of Small intestinal obstruction with INFLIXIMAB
0.3%
of all INFLIXIMAB reports
3
Deaths
296
Hospitalizations

How Dangerous Is Small intestinal obstruction From INFLIXIMAB?

Of the 351 reports, 3 (0.9%) resulted in death, 296 (84.3%) required hospitalization, and 1 (0.3%) were considered life-threatening.

Is Small intestinal obstruction Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for INFLIXIMAB. However, 351 reports have been filed with the FAERS database.

What Other Side Effects Does INFLIXIMAB Cause?

Off label use (34,801) Drug ineffective (33,738) Condition aggravated (16,616) Rheumatoid arthritis (16,251) Pain (15,061) Fatigue (13,473) Arthralgia (13,441) Infusion related reaction (12,946) Product use issue (12,752) Drug intolerance (11,173)

What Other Drugs Cause Small intestinal obstruction?

ADALIMUMAB (1,665) VEDOLIZUMAB (341) BEVACIZUMAB (268) RISANKIZUMAB-RZAA (241) DOXORUBICIN (237) CLOZAPINE (211) PREDNISONE (190) CARBOPLATIN (178) FLUOROURACIL (178) CYCLOPHOSPHAMIDE (165)

Which INFLIXIMAB Alternatives Have Lower Small intestinal obstruction Risk?

INFLIXIMAB vs INFLIXIMAB-ABDA INFLIXIMAB vs INFLIXIMAB-AXXQ INFLIXIMAB vs INFLIXIMAB-DYYB INFLIXIMAB vs INFLIXIMAB-QBTX INFLIXIMAB vs INFLIXIMAB, RECOMBINANT

Related Pages

INFLIXIMAB Full Profile All Small intestinal obstruction Reports All Drugs Causing Small intestinal obstruction INFLIXIMAB Demographics